Syringin protects against colitis by ameliorating inflammation

Area of Science:

• Gastroenterology
• Pharmacology
• Molecular Biology

Background:

• Inflammatory bowel disease (IBD) is a chronic condition with significant incidence.
• Syringin possesses known anti-inflammatory properties, but its role in IBD remains unexplored.

Purpose of the Study:

• To investigate the therapeutic potential of syringin in inflammatory bowel disease (IBD).
• To elucidate the molecular mechanisms underlying syringin's anti-inflammatory effects in colitis models.

Main Methods:

• Established dextran sulfate sodium (DSS)-induced colitis model in vivo.
• Utilized lipopolysaccharide (LPS)-stimulated rat intestinal epithelial IEC6 cells in vitro.
• Assessed cytokine levels, inflammatory markers (iNOS, COX-2), and key signaling pathways (NF-κB, Nrf2).

Main Results:

• Syringin significantly inhibited the overproduction of proinflammatory cytokines (IL-1β, IL-6, TNF-α) and inflammatory mediators (iNOS, COX-2).
• Syringin inactivated the NF-κB p65 pathway by reducing IκBα phosphorylation.
• Syringin promoted the activation of the antioxidant Nrf2 signaling pathway.
• Syringin's anti-inflammatory effects were comparable to NF-κB inhibitor PDTC and Nrf2 activator RTA408.

Conclusions:

• Syringin demonstrates protective effects against intestinal inflammation in colitis.
• Syringin exerts its anti-inflammatory action by inhibiting the NF-κB pathway and activating the Nrf2 signaling pathway.